| Year of Transplant | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | ||
| Transplants | 70 | 73 | 82 | 113 | 107 | 116 | 152 | 178 | 175 | 198 | |
| Tx with Follow-up Immunosuppression Info | 34 | 37 | 55 | 69 | 73 | 88 | 113 | 130 | 120 | 139 | |
| Corticosteroids | Any in Category | 97.1% | 100.0% | 100.0% | 85.5% | 90.4% | 83.0% | 78.8% | 79.2% | 86.7% | 85.6% |
| Steroids | 97.1% | 100.0% | 100.0% | 85.5% | 90.4% | 83.0% | 78.8% | 79.2% | 86.7% | 85.6% | |
| Cyclosporine | Any in Category | 2.9% | 2.7% | 0.0% | 0.0% | 1.4% | 0.0% | 0.9% | 1.5% | 1.7% | 1.4% |
| Sandimmmune | 0.0% | 2.7% | 0.0% | 0.0% | 1.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.7% | |
| Neoral | 2.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.9% | 0.8% | 1.7% | 0.7% | |
| Gengraf | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.8% | 0.0% | 0.0% | |
| Tacrolimus | Any in Category | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 98.9% | 97.3% | 98.5% | 98.3% | 97.1% |
| Tacrolimus | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 98.9% | 97.3% | 98.5% | 98.3% | 97.1% | |
| Antimetabolites | Any in Category | 41.2% | 37.8% | 14.5% | 15.9% | 11.0% | 10.2% | 12.4% | 20.0% | 16.7% | 18.7% |
| Mycophenolate Mofetil | 35.3% | 21.6% | 14.5% | 2.9% | 9.6% | 10.2% | 8.0% | 13.8% | 13.3% | 12.9% | |
| Azathioprine | 5.9% | 16.2% | 0.0% | 13.0% | 1.4% | 0.0% | 4.4% | 6.2% | 3.3% | 5.8% | |
| mTOR Inhibitors | Any in Category | 0.0% | 21.6% | 69.1% | 24.6% | 28.8% | 15.9% | 22.1% | 23.8% | 19.2% | 10.8% |
| Sirolimus | 0.0% | 21.6% | 69.1% | 24.6% | 28.8% | 15.9% | 22.1% | 23.8% | 19.2% | 10.8% | |
| Everolimus | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |